Prognostic analysis of chemotherapy with concurrent three-dimensional radiotherapy for non-oligometastatic Stage Ⅳ NSCLC
Sheng-fa SU,Yin-xiang HU,Wei-wei OUYANG,Zhu MA,Qing-song LI,Juan CHEN,Jing ZHANG,Ming-yuan HE,Hui-qin LI,Zhi-xu HE,Bing LU
DOI: https://doi.org/10.16073/j.cnki.cjcpt.2017.05.008
2017-01-01
Abstract:OBJECTIVE The role of radiation therapy in addition to chemotherapy has not been well established in non-oligometastatic Stage Ⅳ non-small cell lung cancer (NSCLC).We aimed to investigate overall survival (OS) of non-oligometastatic NSCLC treated with chemotherapy with concurrent radiation to the primary tumor.METHODS From January 23,2003 to May 13,2012.Totally 404 patients were enrolled in two prospective studies.Totally,274 eligible patients were screened from these two prospective studies.Main eligible criteria were as follows:(1) histologically or cytology confirmed NSCLC;(2) age 18-80 years;(3) a Karnofsky Performance Status (KPS) score ≥70;(4) received at least two chemotherapy cycles,and did not receive targeted therapy or immunotherapy during lifetime;(5) using modern radiation technique (3-dimensional conformal radiation therapy [3DCRT] or intensity modulated radiation therapy [IM-RT]);(6) a thoracic radiation dose of at least 36 Gy.Oligometastatic and non-oligometastatic NSCLC were defined as having ＜ 5 and ≥5 metastatic lesions,respectively.Prognostic factors for OS were identified using univariate and multivariate analysis.RESULTS Totally 274 eligible patients were included in this study,183 had non-oligometastatic disease.The median OS time for all patients was 13.0 months (95％ CI:11.9-14.1),and the OS rates were 50.7％ at 1 year,15.8％ at 2 years,and 9.1％ at 3 years.OS rates for patients who had received ≥63 Gy thoracic radiation therapy were 55.3％ at 1 year,22.7％ at 2 years,and 17.0％ at 3 years.Corresponding rates for those who received ＜63 Gy were 46.5％,9.3％,and 2.5％ (x2 =11.497,P＜0.001).Comparison of OS in patients with oligometastatic disease versus those with non-oligometastatic disease,the 1-,2-,and 3-year OS rates were 59.3％,22.0％ and 15.2％ vs 46.4％,12.7％ and 6.0％ (x2 =5.741,P=0.017).When all patients were subdivided into patients with oligometastase (x2 =7.571,P=0.006) and non-oligometastase(x2=8.242,P=0.004),a radiation dose≥63 Gy remained a significant prognostic factor for better OS.For non-oligometastatic patients,multivariate analysis showed that receiving ≥63 Gy radiation,having a GTV ＜146 cm3,having response to chemotherapy,and having stable or increased post-treatment KPS independently predicted better OS.Among non-oligometastatic patients with response to chemotherapy,patients who received≥63 Gy to the primary tumor had a better OS than those receiving ＜ 63 Gy (x2 =4.419,P=0.036).Among patients without response to chemotherapy,this difference was not statistically significant (x2=1.947,P=0.163).CONCLUSIONS Radiation dose,primary tumor volume,response to chemotherapy and KPS after treatment are associated with OS in patients with non-oligometastatic disease.On basis of effective system chemotherapy,aggressive thoracic radiotherapy may prolong OS.